Starlink is expanding into Vietnam with a focus on improving healthcare connectivity.The goal: enable telemedicine, remote consultations, and digital health infrastructure. https://t.co/zVYfzTycQo ...

Company earns Gold for its NCQA-accredited health navigation platform for large employers and commercial health plans, immersive medical animation, and doctor-patient communications supportATLANTA, June 23, 2025 (GLOBE NEWSWIRE) -- Sharecare, the health tech company that helps to improve care quality, drive better outcomes, and lower costs across the healthcare ecosystem, today announced it has won 21 Digital Health Awards in the Health Information Resource Center’s Spring 2025 competition. Now in its 27th ...

Key Takeaways CVS stock has jumped 53.7% in 2025 on strong operations and a friendlier regulatory landscape. Removal of PBM and Medicare Advantage cuts boosts CVS' Caremark and Aetna business lines. CVS' digital care push, cost savings and expanded access are reinforcing its 2025 growth trajectory.CVS Health (CVS) has seen its stock surge by 53.7% in 2025, fueled by a potent combination of strong operational performance and a favorable regulatory outlook. The company raised its full-year 2025 EPS guidance ...

Core Viewpoint - DXS International plc's digital medicine solution, ExpertCare, has been selected for the Grow Digital Health Midlands Programme, aimed at scaling digital health innovations across the NHS and broader care system [1][2]. Group 1: Programme Details - The Grow Digital Health Midlands Programme is a collaboration between Health Innovation East Midlands and Health Innovation West Midlands, featuring nine high-potential digital health companies, including DXS [2]. - The programme aims to support UK technology innovators in addressing NHS challenges, focusing on enhancing productivity and communication while reducing hospital care demand [3][4]. Group 2: Selection Process - A total of 51 applications were received, with nine companies selected to receive tailored support, including exposure to NHS England's largest region, covering 11 Integrated Care Systems and a population of approximately 11.8 million [3]. - The selection criteria emphasized the relevance of solutions to NHS priorities and technology readiness [4]. Group 3: Government Alignment - The programme aligns with the UK government's 10 Year Health Plan, which aims to transition from an analogue to a digital system, shift care from hospitals to community settings, and focus on health prevention rather than treatment [5]. Group 4: Company Overview - DXS International provides clinical decision support by presenting up-to-date treatment guidelines from trusted NHS sources to healthcare professionals, ultimately improving healthcare outcomes and contributing to NHS efficiency savings [8].

Key Takeaways Hims The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS) , has been leveraging existing capabilities and continuing to expand capabilities to penetrate new sales channels and further improve operations. Per management, HIMS’ model has been developed to be scalable and applicable across new markets and languages. The company expanded into the U.K. in early 2021, and in June 2021, it completed the acquisition of U.K.-based Honest Health Limited, which is now Hims & Hers UK ...

AptarGroup (ATR) 2025 Conference June 04, 2025 02:00 PM ET Speaker0 Afternoon. I'm Dan Rizzo with Jefferies Equity Research. Presenting now is Aptar Group, and with us today is CEO, Stefan Tanda, and CFO, Vanessa Cano. There'll be a presentation, but there should be time at the end for questions. So with that, I will turn it over to Stefan. Thanks. Speaker1 Alright, Dan. Thanks for having us. It's my pleasure to introduce you to Aptar Group. It's, I think, our inaugural presence at this, conference. The rea ...

Company Overview - Hims & Hers Health, Inc. (HIMS) has announced its agreement to acquire ZAVA, a digital health platform in Europe, marking a significant step toward global expansion [1][3] - The acquisition is expected to close in the second half of 2025 and is anticipated to be accretive by 2026 [1][10] Expansion Plans - The deal will expand HIMS' footprint in the U.K. and officially launch the company into Germany, France, and Ireland, with more markets expected soon [1][2] - Hims & Hers plans to introduce a personalized dimension of digital health in Europe, providing tailored access to care across various health sectors [2] Market Position and Financials - Hims & Hers currently has a market capitalization of $12.25 billion and an earnings yield of 1.3%, which is favorable compared to the industry's negative yield [5] - The company delivered an earnings surprise of 66.7% in the last reported quarter [5] Strategic Rationale - The acquisition aims to leverage ZAVA's established European presence to enhance access to care for individuals facing chronic conditions like obesity and depression [6][7] - ZAVA currently serves over 1.3 million active customers and has conducted nearly 2.3 million consultations in 2024 across the U.K., Germany, France, and Ireland [6] Industry Prospects - The global digital health market was estimated at $288.55 billion in 2024 and is expected to grow at a CAGR of 22.2% from 2025 to 2030, driven by rising chronic conditions and technological advancements [8] - The latest acquisition is seen as a significant milestone for Hims & Hers, potentially boosting its global business [9] Stock Performance - Following the acquisition announcement, HIMS shares lost nearly 3.6% until the previous day's closing, despite historical synergies from strategic buyouts [4] - Over the past year, HIMS shares have surged 154.1%, outperforming the industry and the S&P 500 [13]

Demographic Trends - The global population is aging rapidly, with life expectancies increasing and birth rates declining, leading to a demographic imbalance in both developed and emerging economies [1] - By 2030, one in six individuals globally will be over 60, and by 2050, this figure is expected to reach 2.1 billion, with 80% residing in low- and middle-income countries [2] Healthcare Market Dynamics - The global geriatric care market was valued at approximately $1.2 trillion in 2025, up from around $1 trillion in 2022, driven by the rising prevalence of chronic conditions among older adults [3] - There is a growing demand for pharmaceuticals, medical devices, home-based care, and digital health solutions tailored for aging populations [3] Company Strategies - Healthcare companies like Boston Scientific, AbbVie, Amgen, and Dexcom are enhancing operational efficiency to expand their presence in the Seniors & Aging Demographics domain [4] - Pharmaceutical companies are focusing on developing treatments for chronic conditions prevalent in older adults, particularly in immunology, oncology, and neurodegenerative diseases [5] Investment Opportunities - The Healthcare Real Estate Investment Trust (Healthcare REIT) sector is gaining attention, with companies like Community Healthcare Trust and CareTrust REIT focusing on specialized healthcare real estate for the aging population [6] - Digital health solutions, AI-driven diagnostics, and home-based monitoring systems are creating new revenue opportunities for healthcare firms [5] Company Highlights - Boston Scientific has developed devices like the WATCHMAN and SYNERGY systems, catering to the needs of elderly patients [8] - AbbVie is expanding its focus on the aging demographic through strategic acquisitions and partnerships, including the acquisition of Aliada Therapeutics for Alzheimer's treatment [10][11] - Amgen is advancing its R&D pipeline with a focus on elderly-targeted medicines, including osteoporosis treatments and obesity drugs [13][14][15] - Dexcom is enhancing its continuous glucose monitoring systems for seniors, including the launch of the Stelo system, which is designed for ease of use [16][17]

Key Takeaways Boston Scientific saw 9.8% operational sales growth in emerging markets in Q1 2025 despite geopolitical risks. BSX benefits from favorable economic trends, healthcare infrastructure and sustained investment. BSX competes with ABT and MDT, which also report strong emerging market growth and localization efforts.Emerging markets remain a vital growth engine for Boston Scientific Corporation (BSX) , anchoring the company’s broader international strategy and long-term expansion plans. In the fir ...

Hims & Hers Health (NYSE: HIMS) experienced a notable uptick in its stock price following the announcement of its planned acquisition of ZAVA, a prominent European digital health platform. The stock rose 7.77% in pre-market trading on June 3, 2025, reflecting investor optimism about the company’s strategic expansion into Europe. HIMS shares closed at $56.77 on Monday, reflecting a year-to-date increase of approximately 134.78% and a 39.07% gain over the past month. HIMS stock climbs over 7% in pre-market. S ...